Form SC 13D LUMOS PHARMA, INC. Filed by: Blackstone Holdings II L.P.
Lumos Pharma, Inc. (LUMO)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
LUMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUMO alerts
High impacting Lumos Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LUMO
News
- Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action [Yahoo! Finance]Yahoo! Finance
- Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of ActionGlobeNewswire
- Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMOGlobeNewswire
- Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024GlobeNewswire
LUMO
Earnings
- 8/1/24 - Beat
LUMO
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- LUMO's page on the SEC website